nisoldipine has been researched along with Cardiovascular Stroke in 52 studies
Nisoldipine: A dihydropyridine calcium channel antagonist that acts as a potent arterial vasodilator and antihypertensive agent. It is also effective in patients with cardiac failure and angina.
nisoldipine : A racemate consisting of equimolar amounts of (R)- and (S)-nisoldipine. A calcium channel blocker, it is used in the treatment of hypertension and angina pectoris.
methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a methoxycarbonyl group at position 3, an o-nitrophenyl group at position 4, and an isobutoxycarbonyl group at position 5. The racemate, a calcium channel blocker, is used in the treatment of hypertension and angina pectoris.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of the present study was to test whether the administration of a vascular-selective organic calcium antagonist (nisoldipine) at the onset of early mechanical reperfusion (by coronary angioplasty) in acute myocardial infarction could prevent or attenuate postischemic stunning and enhance the recovery of left ventricular function in these patients." | 9.08 | Recovery of left ventricular function following early reperfusion in acute myocardial infarction: a potential role for the calcium antagonist nisoldipine. ( Chizzoni, A; Marini, A; Sheiban, I; Tonni, S; Trevi, G, 1997) |
| "Analysis of the 470 patients in the trial who had hypertension (base-line diastolic blood pressure, > or = 90 mm Hg) showed similar control of blood pressure, blood glucose and lipid concentrations, and smoking behavior in the nisoldipine group (237 patients) and the enalapril group (233 patients) throughout five years of follow-up." | 9.08 | The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. ( Biggerstaff, SL; Estacio, RO; Gifford, N; Hiatt, WR; Jeffers, BW; Schrier, RW, 1998) |
| "The effects of the second generation calcium channel blocking drug nisoldipine on subjective and objective measurements of exercise performance were studied in 19 patients with moderate to severe heart failure (9 New York Heart Association functional class 2, 9 class 3 and 1 class 4) due to fixed ventricular dysfunction following myocardial infarction." | 9.07 | Effect of nisoldipine on exercise performance in heart failure following myocardial infarction. ( Flugelman, MY; Front, A; Halon, DA; Hardoff, R; Lewis, BS; Makhoul, N; Merdler, A, 1991) |
| "The DEFIANT-I study (Doppler Flow and Echocardiography in Functional cardiac Insufficiency: Assessment of Nisoldipine Therapy) was a multicenter, multinational double-blind randomized study of the effects of the new calcium channel blocking drug nisoldipine on left ventricular (LV) size and function after acute myocardial infarction." | 9.07 | The DEFIANT study of left ventricular function and exercise performance after acute myocardial infarction. Doppler Flow and Echocardiology in Functional Cardiac Insufficiency: Assessment of Nisoldipine Therapy Study Group. ( Lewis, BS; Poole-Wilson, PA, 1994) |
| "The aim of the study was to investigate the hemodynamic effects of a short-acting, potent, highly specific calcium antagonist, nisoldipine, in patients with acute myocardial infarction." | 9.07 | Hemodynamic effects of nisoldipine, a highly specific calcium antagonist, in patients with acute myocardial infarction. ( Commerford, PJ; Millar, RS; Opie, LH; Wilson, J, 1992) |
| "Echocardiographic and Doppler-derived measurements of left ventricular (LV) function at rest were examined as predictors of maximal bicycle exercise capacity in a homogeneous group of 115 patients with mild to moderate LV dysfunction (ejection fraction 22 to 56%, median 43%) participating in the DEFIANT study of nisoldipine after acute myocardial infarction." | 9.07 | Left ventricular systolic and diastolic function, and exercise capacity six to eight weeks after acute myocardial infarction. The DEFIANT Study Group. Doppler Flow and Echocardiography in Functional Cardiac Insufficiency: Assessment of Nisoldipine Therapy ( Emmott, SN; Lewis, BS; Lubsen, J; MacNeill, AB; Smyllie, J, 1993) |
| "A multicentre, randomized, double-blind, placebo-controlled, parallel-group trial was undertaken in 135 patients to determine whether 4 weeks of treatment with long-acting nisoldipine coat-core (20 mg once a day) could alter diastolic function in patients with a recent myocardial infarction and with mild left ventricular dysfunction as indicated by a left ventricular ejection fraction < or = 50%." | 9.07 | Improved diastolic function with the calcium antagonist nisoldipine (coat-core) in patients post myocardial infarction: results of the DEFIANT study. Doppler Flow and Echocardiography in Functional cardiac Insufficiency: Assessment of Nisoldipine Therapy. ( , 1992) |
| "The effects of the long-acting dihydropyridine calcium antagonist nisoldipine coat core (CC) have been investigated in > 3,500 patients with angina pectoris, hypertension, and ischemic ventricular dysfunction." | 8.79 | Efficacy and safety of nisoldipine coat core in the management of angina pectoris, systemic hypertension, and ischemic ventricular dysfunction. ( Lewis, BS, 1995) |
| "m-Nisoldipine iv 3, 5 and 10 micrograms/kg before coronary artery ligation markedly reduced the early ischemic arrhythmia in conscious rats." | 7.67 | [Effects of m-nisoldipine on ischemic arrhythmia in conscious rats]. ( An, RH; Fu, SX; Li, YS, 1989) |
| "The acute effects on left ventricular function of nisoldipine were studied in six patients 56 +/- 12 hours (range 44 to 72 hours) after the onset of uncomplicated acute myocardial infarction." | 7.67 | The acute effects of intravenous nisoldipine on left ventricular function 24 to 72 hours after uncomplicated acute myocardial infarction. ( Arndt, JW; Blokland, JA; Bruschke, AV; Cats, VM; de Nooijer, RC; Jaarsma, W; van der Laarse, A; van der Wall, EE; van Herpen, G, 1988) |
| "Treatment with nisoldipine had no influence on LV volumes in either of the two groups or in the total study group." | 6.69 | Left ventricular remodelling in post-myocardial infarction patients with left ventricular ejection fraction 40-50% vs 25-39%. Influence of nisoldipine treatment? An echocardiographic substudy from the DEFIANT II study. ( Kirwan, B; Lubsen, K; Otterstad, JE; Parker, A; Plappert, T; St John Sutton, MG, 1999) |
| "Nisoldipine is a calcium antagonist with potent coronary vasodilating effects in patients with chronic stable angina pectoris." | 6.67 | Acute effects of intravenous nisoldipine on left ventricular function after acute myocardial infarction. ( Bruschke, AV; Cats, VM; Chin, JC; Pauwels, EJ; van der Wall, EE, 1994) |
| "Nisoldipine produced an increase in pump function (+2%) in the group with extremely decreased EF up to 9% in some individual cases." | 6.67 | Effects of calcium antagonists in patients with coronary disease and heart failure: left ventricular function following nisoldipine measured by radionuclide ventriculography. ( Eichstaedt, H, 1992) |
| "Nisoldipine is a second-generation dihydropyridine calcium channel blocker (CCB)." | 6.40 | Nisoldipine CC: efficacy and tolerability in hypertension and ischemic heart disease. ( Fodor, JG, 1997) |
| "Nisoldipine was more effective in preventing cardiac necrosis as compared to nitrendipine and nimodipine." | 5.29 | Effect of nitrendipine, nimodipine and nisoldipine on experimentally induced myocardial infarction in rats. ( Kaur, AH; Mathur, SK; Singh, J; Srivastava, RK, 1995) |
| "Nisoldipine is a calcium antagonist with potent coronary vasodilating effects in patients with chronic stable angina pectoris." | 5.28 | The acute effects of intravenous nisoldipine on left ventricular function within 24 h after acute myocardial infarction. ( Blokland, JA; Bruschke, AV; Chin, JC; Manger Cats, V; Pauwels, EJ; van der Laarse, A; van der Wall, EE, 1992) |
| " The equi-effective dosage was 0." | 5.27 | Comparison of the acute hemodynamic response to intravenous nisoldipine (Bay k 5552) and intravenous nifedipine for left ventricular dysfunction secondary to myocardial infarction. ( Aschenberg, W; Bleifeld, W; Clausen, A; Fehr, A; Nienaber, CA; Spielmann, RP, 1987) |
| "The NICOLE study (NIsoldipine in COronary artery disease in LEuven) is a single centre, randomised, double blind, placebo controlled trial with coronary angiography at baseline, six months, and three years of follow up." | 5.10 | Long term effects of nisoldipine on the progression of coronary atherosclerosis and the occurrence of clinical events: the NICOLE study. ( Coussement, P; De Scheerder, IK; Dens, JA; Desmet, WJ; Kerdsinchai, P; Kostopoulos, K; Piessens, JH; Supanantaroek, C, 2003) |
| "A multicentre, double-blind, placebo-controlled trial was conducted in 542 patients, randomized 7-10 days after myocardial infarction, to study the effect of nisoldipine coat-core (nisoldipine-CC) on exercise after 6 months." | 5.08 | Doppler flow and echocardiography in functional cardiac insufficiency: assessment of nisoldipine therapy. Results of the DEFIANT-II Study. The DEFIANT-II Research Group. ( , 1997) |
| "The purpose of the present study was to test whether the administration of a vascular-selective organic calcium antagonist (nisoldipine) at the onset of early mechanical reperfusion (by coronary angioplasty) in acute myocardial infarction could prevent or attenuate postischemic stunning and enhance the recovery of left ventricular function in these patients." | 5.08 | Recovery of left ventricular function following early reperfusion in acute myocardial infarction: a potential role for the calcium antagonist nisoldipine. ( Chizzoni, A; Marini, A; Sheiban, I; Tonni, S; Trevi, G, 1997) |
| "Analysis of the 470 patients in the trial who had hypertension (base-line diastolic blood pressure, > or = 90 mm Hg) showed similar control of blood pressure, blood glucose and lipid concentrations, and smoking behavior in the nisoldipine group (237 patients) and the enalapril group (233 patients) throughout five years of follow-up." | 5.08 | The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. ( Biggerstaff, SL; Estacio, RO; Gifford, N; Hiatt, WR; Jeffers, BW; Schrier, RW, 1998) |
| "Echocardiographic and Doppler-derived measurements of left ventricular (LV) function at rest were examined as predictors of maximal bicycle exercise capacity in a homogeneous group of 115 patients with mild to moderate LV dysfunction (ejection fraction 22 to 56%, median 43%) participating in the DEFIANT study of nisoldipine after acute myocardial infarction." | 5.07 | Left ventricular systolic and diastolic function, and exercise capacity six to eight weeks after acute myocardial infarction. The DEFIANT Study Group. Doppler Flow and Echocardiography in Functional Cardiac Insufficiency: Assessment of Nisoldipine Therapy ( Emmott, SN; Lewis, BS; Lubsen, J; MacNeill, AB; Smyllie, J, 1993) |
| "To assess the effects of nisoldipine on chronically underperfused myocardial areas ("hibernating myocardium"), the global and regional left ventricular (LV) function was analyzed before and after 2 months of double-blind monotherapy with nisoldipine (10 mg twice daily) or placebo in 17 patients with a previous anterior myocardial infarction." | 5.07 | Effects of prolonged nisoldipine administration on the "hibernating" myocardium. ( Gurné, O; Pouleur, H; Rousseau, MF; van Eyll, C, 1992) |
| "A multicentre, randomized, double-blind, placebo-controlled, parallel-group trial was undertaken in 135 patients to determine whether 4 weeks of treatment with long-acting nisoldipine coat-core (20 mg once a day) could alter diastolic function in patients with a recent myocardial infarction and with mild left ventricular dysfunction as indicated by a left ventricular ejection fraction < or = 50%." | 5.07 | Improved diastolic function with the calcium antagonist nisoldipine (coat-core) in patients post myocardial infarction: results of the DEFIANT study. Doppler Flow and Echocardiography in Functional cardiac Insufficiency: Assessment of Nisoldipine Therapy. ( , 1992) |
| "The aim of the study was to investigate the hemodynamic effects of a short-acting, potent, highly specific calcium antagonist, nisoldipine, in patients with acute myocardial infarction." | 5.07 | Hemodynamic effects of nisoldipine, a highly specific calcium antagonist, in patients with acute myocardial infarction. ( Commerford, PJ; Millar, RS; Opie, LH; Wilson, J, 1992) |
| "The long-term effects of oral nisoldipine or placebo on clinical variables, exercise test results and echo Doppler-determined systolic and diastolic functions were studied in 30 consecutive patients with reduced left ventricular function (predischarge echocardiographic wall motion score greater than or equal to 8) following myocardial infarction." | 5.07 | Effects of nisoldipine on systolic and diastolic function in postinfarction patients with reduced left ventricular function: a randomized, double-blind, placebo controlled study. ( de Cock, CC; Kamp, O; Peels, KH; Roos, JP; van Eenige, J; Visser, FC, 1991) |
| "The effects of the second generation calcium channel blocking drug nisoldipine on subjective and objective measurements of exercise performance were studied in 19 patients with moderate to severe heart failure (9 New York Heart Association functional class 2, 9 class 3 and 1 class 4) due to fixed ventricular dysfunction following myocardial infarction." | 5.07 | Effect of nisoldipine on exercise performance in heart failure following myocardial infarction. ( Flugelman, MY; Front, A; Halon, DA; Hardoff, R; Lewis, BS; Makhoul, N; Merdler, A, 1991) |
| "The DEFIANT-I study (Doppler Flow and Echocardiography in Functional cardiac Insufficiency: Assessment of Nisoldipine Therapy) was a multicenter, multinational double-blind randomized study of the effects of the new calcium channel blocking drug nisoldipine on left ventricular (LV) size and function after acute myocardial infarction." | 5.07 | The DEFIANT study of left ventricular function and exercise performance after acute myocardial infarction. Doppler Flow and Echocardiology in Functional Cardiac Insufficiency: Assessment of Nisoldipine Therapy Study Group. ( Lewis, BS; Poole-Wilson, PA, 1994) |
| "The effects of the long-acting dihydropyridine calcium antagonist nisoldipine coat core (CC) have been investigated in > 3,500 patients with angina pectoris, hypertension, and ischemic ventricular dysfunction." | 4.79 | Efficacy and safety of nisoldipine coat core in the management of angina pectoris, systemic hypertension, and ischemic ventricular dysfunction. ( Lewis, BS, 1995) |
| "To investigate the clinical applicability of the three-dimensional (3D) myocardial imaging using a newly developed system (the Application Visualization System-Medical Viewer), thallium-201 myocardial single photon emission computed tomography was performed in 19 patients with previous myocardial infarction before and after treatment with nisoldipine." | 3.69 | Clinical application of three-dimensional myocardial imaging: evaluation of efficacy of medical treatment on myocardial perfusion. ( Hosoi, H; Ishiguro, S; Morishita, T; Muto, H; Sugita, J; Takahashi, M; Takano, M; Yamashina, H; Yamazaki, J, 1996) |
| "m-Nisoldipine iv 3, 5 and 10 micrograms/kg before coronary artery ligation markedly reduced the early ischemic arrhythmia in conscious rats." | 3.67 | [Effects of m-nisoldipine on ischemic arrhythmia in conscious rats]. ( An, RH; Fu, SX; Li, YS, 1989) |
| " Among 15 patients with coronary artery disease who had been treated with nisoldipine, onset of severe unstable angina was observed in 2 and evolution of acute myocardial infarction in 1 patient after abrupt withdrawal of nisoldipine therapy." | 3.67 | Calcium-blocker withdrawal phenomenon: increase in affinity of alpha 2 adrenoceptors for agonist as a potential mechanism. ( Lopez, LM; Mehta, J, 1986) |
| "The acute effects on left ventricular function of nisoldipine were studied in six patients 56 +/- 12 hours (range 44 to 72 hours) after the onset of uncomplicated acute myocardial infarction." | 3.67 | The acute effects of intravenous nisoldipine on left ventricular function 24 to 72 hours after uncomplicated acute myocardial infarction. ( Arndt, JW; Blokland, JA; Bruschke, AV; Cats, VM; de Nooijer, RC; Jaarsma, W; van der Laarse, A; van der Wall, EE; van Herpen, G, 1988) |
| "The intravenous administration of either nifedipine (in doses of 5-50 microgram/kg), or nisoldipine (5-1000 microgram/kg) markedly reduced, or abolished, the serious ventricular arrhythmias (tachycardia and fibrillation) that result from acute coronary artery artery ligation in pentobarbitone-anaesthetized rats." | 3.66 | Calcium antagonists prevent early post-infarction ventricular fibrillation. ( Fagbemi, O; Parratt, JR, 1981) |
| "Treatment with nisoldipine had no influence on LV volumes in either of the two groups or in the total study group." | 2.69 | Left ventricular remodelling in post-myocardial infarction patients with left ventricular ejection fraction 40-50% vs 25-39%. Influence of nisoldipine treatment? An echocardiographic substudy from the DEFIANT II study. ( Kirwan, B; Lubsen, K; Otterstad, JE; Parker, A; Plappert, T; St John Sutton, MG, 1999) |
| "Nisoldipine produced an increase in pump function (+2%) in the group with extremely decreased EF up to 9% in some individual cases." | 2.67 | Effects of calcium antagonists in patients with coronary disease and heart failure: left ventricular function following nisoldipine measured by radionuclide ventriculography. ( Eichstaedt, H, 1992) |
| "Nisoldipine is a calcium antagonist with potent coronary vasodilating effects in patients with chronic stable angina pectoris." | 2.67 | Acute effects of intravenous nisoldipine on left ventricular function after acute myocardial infarction. ( Bruschke, AV; Cats, VM; Chin, JC; Pauwels, EJ; van der Wall, EE, 1994) |
| "Nisoldipine is a second-generation dihydropyridine calcium channel blocker (CCB)." | 2.40 | Nisoldipine CC: efficacy and tolerability in hypertension and ischemic heart disease. ( Fodor, JG, 1997) |
| "Nisoldipine was more effective in preventing cardiac necrosis as compared to nitrendipine and nimodipine." | 1.29 | Effect of nitrendipine, nimodipine and nisoldipine on experimentally induced myocardial infarction in rats. ( Kaur, AH; Mathur, SK; Singh, J; Srivastava, RK, 1995) |
| "Nisoldipine is a calcium antagonist with potent coronary vasodilating effects in patients with chronic stable angina pectoris." | 1.28 | The acute effects of intravenous nisoldipine on left ventricular function within 24 h after acute myocardial infarction. ( Blokland, JA; Bruschke, AV; Chin, JC; Manger Cats, V; Pauwels, EJ; van der Laarse, A; van der Wall, EE, 1992) |
| " The equi-effective dosage was 0." | 1.27 | Comparison of the acute hemodynamic response to intravenous nisoldipine (Bay k 5552) and intravenous nifedipine for left ventricular dysfunction secondary to myocardial infarction. ( Aschenberg, W; Bleifeld, W; Clausen, A; Fehr, A; Nienaber, CA; Spielmann, RP, 1987) |
| "Nisoldipine is a potent peripheral and coronary vasodilator free of major myocardial depressant effects after acute intravenous administration." | 1.27 | Coronary and systemic hemodynamic effects of intravenous nisoldipine. ( De Feyter, PJ; Hugenholtz, PG; Serruys, PW; Soward, AL, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (15.38) | 18.7374 |
| 1990's | 38 (73.08) | 18.2507 |
| 2000's | 6 (11.54) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mehler, PS | 1 |
| Coll, JR | 1 |
| Estacio, R | 1 |
| Esler, A | 1 |
| Schrier, RW | 4 |
| Hiatt, WR | 2 |
| Dens, JA | 1 |
| Desmet, WJ | 1 |
| Coussement, P | 1 |
| De Scheerder, IK | 1 |
| Kostopoulos, K | 1 |
| Kerdsinchai, P | 1 |
| Supanantaroek, C | 1 |
| Piessens, JH | 1 |
| Fagbemi, O | 1 |
| Parratt, JR | 1 |
| Kaur, AH | 1 |
| Singh, J | 1 |
| Srivastava, RK | 1 |
| Mathur, SK | 1 |
| Brunelli, C | 1 |
| Parodi, O | 1 |
| Sambuceti, G | 1 |
| Corsiglia, L | 1 |
| Rosa, GM | 1 |
| Giorgetti, A | 1 |
| Bezante, GP | 1 |
| Nista, N | 1 |
| Caponnetto, S | 1 |
| Lewis, BS | 4 |
| Nohara, R | 1 |
| Hata, T | 1 |
| Hosokawa, R | 1 |
| Lee, L | 1 |
| Fujita, M | 1 |
| Kambara, H | 1 |
| Sasayama, S | 1 |
| van der Wall, EE | 3 |
| Cats, VM | 2 |
| Chin, JC | 2 |
| Pauwels, EJ | 2 |
| Bruschke, AV | 3 |
| Poole-Wilson, PA | 1 |
| Emmott, SN | 1 |
| Smyllie, J | 1 |
| MacNeill, AB | 1 |
| Lubsen, J | 1 |
| Wallbridge, DR | 1 |
| Schulz, R | 1 |
| Braun, C | 1 |
| Post, H | 1 |
| Heusch, G | 2 |
| Yamazaki, J | 1 |
| Hosoi, H | 1 |
| Ishiguro, S | 1 |
| Muto, H | 1 |
| Yamashina, H | 1 |
| Morishita, T | 1 |
| Takano, M | 1 |
| Sugita, J | 1 |
| Takahashi, M | 1 |
| Romano, M | 1 |
| Cardei, S | 1 |
| de Arcangelis, E | 1 |
| Monteforte, I | 1 |
| Capaldo, M | 1 |
| Muto, P | 1 |
| Marchegiano, R | 1 |
| Kilama, MO | 1 |
| Condorelli, M | 1 |
| Hall, R | 1 |
| Fodor, JG | 1 |
| Sheiban, I | 1 |
| Tonni, S | 1 |
| Chizzoni, A | 1 |
| Marini, A | 1 |
| Trevi, G | 1 |
| Kloner, RA | 1 |
| Przyklenk, K | 1 |
| Nixdorff, U | 1 |
| Erbel, R | 1 |
| Wagner, S | 1 |
| Buck, T | 1 |
| Mertes, H | 1 |
| Mohr-Kahaly, S | 1 |
| Meyer, J | 1 |
| Estacio, RO | 3 |
| Jeffers, BW | 1 |
| Biggerstaff, SL | 1 |
| Gifford, N | 1 |
| Cutler, JA | 1 |
| Osende, JI | 1 |
| Walker, AM | 1 |
| Molitch, ME | 1 |
| St John Sutton, M | 1 |
| Otterstat, JE | 1 |
| Plappert, T | 2 |
| Parker, A | 2 |
| Sekarski, D | 1 |
| Keane, MG | 1 |
| Poole-Wilson, P | 1 |
| Lubsen, K | 2 |
| Fink, KS | 1 |
| Ellsworth, A | 1 |
| Otterstad, JE | 1 |
| Kirwan, B | 1 |
| St John Sutton, MG | 1 |
| Huang, B | 1 |
| Qin, D | 1 |
| Deng, L | 1 |
| Boutjdir, M | 1 |
| E1-Sherif, N | 1 |
| Jiang, M | 1 |
| Cabo, C | 1 |
| Yao, J | 1 |
| Boyden, PA | 1 |
| Tseng, G | 1 |
| Eichstaedt, H | 1 |
| Pouleur, H | 2 |
| van Eyll, C | 2 |
| Gurné, O | 2 |
| Rousseau, MF | 2 |
| Scognamiglio, R | 1 |
| Nistri, S | 1 |
| Fasoli, G | 1 |
| Frigato, N | 1 |
| Miorelli, M | 1 |
| Karavidas, A | 1 |
| Ponchia, A | 1 |
| Dalla-Volta, S | 1 |
| Manger Cats, V | 1 |
| van der Laarse, A | 2 |
| Blokland, JA | 2 |
| Wilson, J | 1 |
| Commerford, PJ | 1 |
| Millar, RS | 1 |
| Opie, LH | 1 |
| Crottogini, AJ | 2 |
| Lascano, EC | 1 |
| Barra, JG | 2 |
| Morales, MC | 1 |
| Depaoli, JR | 2 |
| Pichel, RH | 2 |
| Makhoul, N | 1 |
| Merdler, A | 1 |
| Flugelman, MY | 1 |
| Front, A | 1 |
| Hardoff, R | 1 |
| Halon, DA | 1 |
| de Cock, CC | 1 |
| Visser, FC | 1 |
| Peels, KH | 1 |
| Kamp, O | 1 |
| van Eenige, J | 1 |
| Roos, JP | 1 |
| Sassen, LM | 1 |
| Bezstarosti, K | 1 |
| Verdouw, PD | 1 |
| Lamers, JM | 1 |
| An, RH | 1 |
| Fu, SX | 1 |
| Li, YS | 1 |
| Soward, AL | 1 |
| De Feyter, PJ | 1 |
| Hugenholtz, PG | 1 |
| Serruys, PW | 1 |
| Mehta, J | 1 |
| Lopez, LM | 1 |
| de Nooijer, RC | 1 |
| van Herpen, G | 1 |
| Jaarsma, W | 1 |
| Arndt, JW | 1 |
| Vatner, SF | 1 |
| Patrick, TA | 1 |
| Knight, DR | 1 |
| Manders, WT | 1 |
| Fallon, JT | 1 |
| Nienaber, CA | 1 |
| Spielmann, RP | 1 |
| Aschenberg, W | 1 |
| Fehr, A | 1 |
| Clausen, A | 1 |
| Bleifeld, W | 1 |
| Fischer, EC | 1 |
| Rodríguez Chatruc, M | 1 |
| de la Fuente, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00000542] | Phase 3 | 0 participants | Interventional | 1993-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for nisoldipine and Cardiovascular Stroke
| Article | Year |
|---|---|
Efficacy and safety of nisoldipine coat core in the management of angina pectoris, systemic hypertension, and ischemic ventricular dysfunction.
Topics: Angina Pectoris; Delayed-Action Preparations; Humans; Hypertension; Myocardial Infarction; Nisoldipi | 1995 |
Nisoldipine CC: efficacy and tolerability in hypertension and ischemic heart disease.
Topics: Aging; Angina Pectoris; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Delayed-A | 1997 |
Reversible and irreversible left ventricular dysfunction after acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Echocardiography; Humans; Metoprolol; Myocar | 1992 |
22 trials available for nisoldipine and Cardiovascular Stroke
| Article | Year |
|---|---|
Intensive blood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and type 2 diabetes.
Topics: Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Cohort Studies; Comorbidity; Death | 2003 |
Long term effects of nisoldipine on the progression of coronary atherosclerosis and the occurrence of clinical events: the NICOLE study.
Topics: Calcium Channel Blockers; Coronary Angiography; Coronary Artery Disease; Coronary Stenosis; Disease | 2003 |
Perfusional and metabolic effects of nisoldipine as shown by positron emission tomography after acute myocardial infarction.
Topics: Adult; Coronary Circulation; Coronary Disease; Dobutamine; Echocardiography; Heart; Humans; Myocardi | 1995 |
Effects of nisoldipine in silent myocardial ischemia after healing of acute myocardial infarction.
Topics: Adult; Aged; Dipyridamole; Exercise Tolerance; Female; Hemodynamics; Humans; Male; Middle Aged; Myoc | 1995 |
Acute effects of intravenous nisoldipine on left ventricular function after acute myocardial infarction.
Topics: Adult; Blood Pressure; Cardiac Output; Diastole; Female; Heart Rate; Humans; Infusions, Intravenous; | 1994 |
The DEFIANT study of left ventricular function and exercise performance after acute myocardial infarction. Doppler Flow and Echocardiology in Functional Cardiac Insufficiency: Assessment of Nisoldipine Therapy Study Group.
Topics: Double-Blind Method; Echocardiography, Doppler; Exercise Test; Female; Heart Ventricles; Humans; Mal | 1994 |
Left ventricular systolic and diastolic function, and exercise capacity six to eight weeks after acute myocardial infarction. The DEFIANT Study Group. Doppler Flow and Echocardiography in Functional Cardiac Insufficiency: Assessment of Nisoldipine Therapy
Topics: Adult; Aged; Diastole; Echocardiography; Echocardiography, Doppler; Exercise Test; Exercise Toleranc | 1993 |
Doppler flow and echocardiography in functional cardiac insufficiency: assessment of nisoldipine therapy. Results of the DEFIANT-II Study. The DEFIANT-II Research Group.
Topics: Adult; Aged; Calcium Channel Blockers; Delayed-Action Preparations; Double-Blind Method; Echocardiog | 1997 |
Effects of nisoldipine and/or enalapril on left ventricular function and exercise capacity in patients with recent anterior myocardial infarction and mild cardiac dysfunction.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Drug Therapy, Combination | 1997 |
DEFIANT-II: a study of nisoldipine CC after myocardial infarction. Doppler flow and Echocardiography in Functional cardiac Insufficiency: Assessment of Nisoldipine Therapy investigators.
Topics: Calcium Channel Blockers; Double-Blind Method; Drug Evaluation; Echocardiography; Female; Humans; La | 1997 |
Recovery of left ventricular function following early reperfusion in acute myocardial infarction: a potential role for the calcium antagonist nisoldipine.
Topics: Acute Disease; Adult; Aged; Angioplasty, Balloon; Calcium Channel Blockers; Diastole; Echocardiograp | 1997 |
The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Cardiovascular Dise | 1998 |
Quantitation of left ventricular volumes and ejection fraction in post-infarction patients from biplane and single plane two-dimensional echocardiograms. A prospective longitudinal study of 371 patients.
Topics: Adult; Aged; Cardiac Volume; Double-Blind Method; Echocardiography; Exercise Test; Female; Humans; L | 1998 |
Antihypertensive therapy in type 2 diabetes: implications of the appropriate blood pressure control in diabetes (ABCD) trial.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Calcium Cha | 1998 |
Left ventricular remodelling in post-myocardial infarction patients with left ventricular ejection fraction 40-50% vs 25-39%. Influence of nisoldipine treatment? An echocardiographic substudy from the DEFIANT II study.
Topics: Adult; Aged; Calcium Channel Blockers; Double-Blind Method; Echocardiography; Female; Follow-Up Stud | 1999 |
Effects of calcium antagonists in patients with coronary disease and heart failure: left ventricular function following nisoldipine measured by radionuclide ventriculography.
Topics: Acetyldigoxins; Female; Heart; Heart Failure; Humans; Male; Middle Aged; Myocardial Infarction; Niso | 1992 |
Effects of prolonged nisoldipine administration on the "hibernating" myocardium.
Topics: Double-Blind Method; Heart Rate; Humans; Myocardial Contraction; Myocardial Infarction; Nisoldipine; | 1992 |
Improved diastolic function with the calcium antagonist nisoldipine (coat-core) in patients post myocardial infarction: results of the DEFIANT study. Doppler Flow and Echocardiography in Functional cardiac Insufficiency: Assessment of Nisoldipine Therapy.
Topics: Delayed-Action Preparations; Double-Blind Method; Echocardiography; Exercise Test; Female; Humans; M | 1992 |
Hemodynamic effects of nisoldipine, a highly specific calcium antagonist, in patients with acute myocardial infarction.
Topics: Adult; Aged; Double-Blind Method; Female; Hemodynamics; Humans; Male; Middle Aged; Myocardial Infarc | 1992 |
Analysis of the mechanisms underlying the changes in left ventricular filling dynamics during oral nisoldipine therapy in patients with anterior myocardial infarction.
Topics: Adult; Aged; Cardiac Catheterization; Dose-Response Relationship, Drug; Double-Blind Method; Female; | 1992 |
Effect of nisoldipine on exercise performance in heart failure following myocardial infarction.
Topics: Aged; Double-Blind Method; Exercise Test; Heart Failure; Hemodynamics; Humans; Middle Aged; Myocardi | 1991 |
Effects of nisoldipine on systolic and diastolic function in postinfarction patients with reduced left ventricular function: a randomized, double-blind, placebo controlled study.
Topics: Cardiac Catheterization; Diastole; Double-Blind Method; Echocardiography, Doppler; Exercise Test; Fe | 1991 |
27 other studies available for nisoldipine and Cardiovascular Stroke
| Article | Year |
|---|---|
Calcium antagonists prevent early post-infarction ventricular fibrillation.
Topics: Animals; Arrhythmias, Cardiac; Calcium Channel Blockers; Hemodynamics; Male; Myocardial Infarction; | 1981 |
Effect of nitrendipine, nimodipine and nisoldipine on experimentally induced myocardial infarction in rats.
Topics: Animals; Aspartate Aminotransferases; Calcium Channel Blockers; Female; Heart; Isoproterenol; L-Lact | 1995 |
No attenuation of ischaemic preconditioning by the calcium antagonist nisoldipine.
Topics: Analysis of Variance; Animals; Calcium Channel Blockers; Coronary Circulation; Female; Heart; Hemody | 1996 |
Clinical application of three-dimensional myocardial imaging: evaluation of efficacy of medical treatment on myocardial perfusion.
Topics: Aged; Calcium Channel Blockers; Coronary Circulation; Exercise Test; Female; Heart; Humans; Image Pr | 1996 |
Clinical evidence that nisoldipine attenuates stunning in patients post infarction.
Topics: Angioplasty, Balloon; Animals; Calcium; Calcium Channel Blockers; Dogs; Humans; Myocardial Infarctio | 1997 |
Attenuation of stunning by the calcium antagonist nisoldipine in patients with myocardial infarction and early percutaneous transluminal coronary angioplasty.
Topics: Angioplasty, Balloon; Calcium Channel Blockers; Humans; Myocardial Infarction; Myocardial Reperfusio | 1997 |
Dynamic stress echocardiography for evaluating anti-ischemic drug profiles in post-MI patients.
Topics: Adult; Calcium Channel Blockers; Exercise Test; Female; Humans; Male; Middle Aged; Myocardial Infarc | 1997 |
Calcium-channel blockers for hypertension--uncertainty continues.
Topics: Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Cardiovascular Diseases; Diabete | 1998 |
Calcium blockers questioned.
Topics: Calcium Channel Blockers; Diabetes Mellitus, Type 2; Humans; Hypertension; Myocardial Infarction; Ni | 1998 |
Nisoldipine and myocardial infarction.
Topics: Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Enala | 1998 |
Nisoldipine and myocardial infarction.
Topics: Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Enala | 1998 |
Nisoldipine and myocardial infarction.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Diabetes Mellitus, | 1998 |
Antihypertensive treatment and CHD in the elderly.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; | 1999 |
Reexpression of T-type Ca2+ channel gene and current in post-infarction remodeled rat left ventricle.
Topics: Analysis of Variance; Animals; Animals, Newborn; Calcium Channel Blockers; Calcium Channels, T-Type; | 2000 |
Delayed rectifier K currents have reduced amplitudes and altered kinetics in myocytes from infarcted canine ventricle.
Topics: Analysis of Variance; Animals; Calcium; Calcium Channel Blockers; Dogs; Electrophysiology; Hydantoin | 2000 |
Additional follow-up from the ABCD trial in patients with type 2 diabetes and hypertension.
Topics: Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Cardiovascular Diseases; Diabete | 2000 |
[Blood pressure amplitude in the morning must be reduced. Saving the hypertensive patient from infarct].
Topics: Aged; Blood Pressure; Calcium Channel Blockers; Cerebral Infarction; Circadian Rhythm; Clinical Tria | 2002 |
The acute effects of intravenous nisoldipine on left ventricular function within 24 h after acute myocardial infarction.
Topics: Adult; Cardiac Output; Drug Administration Schedule; Female; Gated Blood-Pool Imaging; Heart Ventric | 1992 |
Effect of long-term oral nisoldipine on infarct size and collateral development in pigs undergoing gradual occlusion of the left circumflex artery.
Topics: Administration, Oral; Animals; Blood Pressure; Coronary Circulation; Coronary Disease; Endocardium; | 1990 |
Effects of nisoldipine on recovery of coronary blood flow, sarcoplasmic reticulum function and other biochemical parameters in post-ischaemic porcine myocardium.
Topics: Animals; Calcium; Calcium-Binding Proteins; Coronary Circulation; Coronary Vessels; Heart; Hemodynam | 1991 |
[Effects of m-nisoldipine on ischemic arrhythmia in conscious rats].
Topics: Animals; Arrhythmias, Cardiac; Blood Flow Velocity; Calcium Channel Blockers; Coronary Circulation; | 1989 |
Coronary and systemic hemodynamic effects of intravenous nisoldipine.
Topics: Adrenergic beta-Antagonists; Adult; Coronary Circulation; Coronary Vessels; Female; Hemodynamics; Hu | 1986 |
Calcium-blocker withdrawal phenomenon: increase in affinity of alpha 2 adrenoceptors for agonist as a potential mechanism.
Topics: Adult; Angina Pectoris; Blood Platelets; Calcium Channel Blockers; Coronary Disease; Epinephrine; Hu | 1986 |
The acute effects of intravenous nisoldipine on left ventricular function 24 to 72 hours after uncomplicated acute myocardial infarction.
Topics: Acute Disease; Adult; Aged; Echocardiography; Humans; Injections, Intravenous; Male; Middle Aged; My | 1988 |
Effects of calcium channel blocker on responses of blood flow, function, arrhythmias, and extent of infarction following reperfusion in conscious baboons.
Topics: Animals; Arrhythmias, Cardiac; Calcium Channel Blockers; Coronary Circulation; Coronary Vessels; Cre | 1988 |
Comparison of the acute hemodynamic response to intravenous nisoldipine (Bay k 5552) and intravenous nifedipine for left ventricular dysfunction secondary to myocardial infarction.
Topics: Aged; Depression, Chemical; Female; Heart Ventricles; Hemodynamics; Humans; Infusions, Intravenous; | 1987 |
The effect of the new calcium antagonist nisoldipine (BAY k-5552) on myocardial infarct size limitation in conscious dogs.
Topics: Animals; Arterial Occlusive Diseases; Blood Pressure; Calcium Channel Blockers; Dogs; Female; Heart | 1985 |